Search Results

Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.

Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.

Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.

Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.